Get startedLog in
    Picture of Elevation Oncology logo

    ELEV — Elevation Oncology News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareSpeculativeMicro CapValue Trap
    All News

    Elevation Oncology Inc expected to post a loss of 19 cents a share - Earnings Preview

    Picture of Elevation Oncology logoElevation Oncology
    28/04/2025 13:58
    Elevation Oncology Inc ELEV.OQ ELEV.O is expected to show no change in quarterly revenue when it reports  results on April 30 (estimated) for the period ending March 31 2025

​LSEG's mean analyst estimate for Elevation Oncology Inc is for a loss of 19 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 5 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts had fallen by about 0.3% in the last three months. ​

Wall Street's median 12-month price target for Elevation Oncology Inc is $1.00​, above​ its last closing price of $0.38. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​


    QUARTER ENDINGSTARMINESMARTESTIMATE®LSEG IBES ESTIMATEACTUALBEAT, MET, MISSEDSURPRISE %
    Dec. 31 2024-0.22-0.22-0.18Beat19.3
    Sep. 30 2024-0.20-0.20-0.22Missed-10.6
    Jun. 30 2024-0.22-0.22-0.18Beat19.5​
    Mar. 31 2024-0.20-0.20-0.23Missed-13.7
    ​​Dec. 31 2023-0.27-0.24-0.19Beat20
    Sep. 30 2023-0.31-0.32-0.25Beat21.9​
    Jun. 30 2023-0.26-0.32-0.37Missed-15
    Mar. 31 2023-0.62-0.59-0.72Missed-21.7
    

This summary was machine generated April 28 at 12:58 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

    Recent news on Elevation Oncology

    See all news